Here's Why Shares of Western Refining Rocketed Ahead 28% in November

Here's Why Shares of Western Refining Rocketed Ahead 28% in November

What happened Shares of refining company Western Refining (NYSE:WNR) climbed 28% in November. The largest reason for the gain wasn’t the news that had so many other refiners gaining ground this past month. Rather, it came following the announcement that Tesoro (NYSE:TSO) would be buying Western for $6.4 billion. So what Western Refining has been → Read More

Is This Why Sarepta Therapeutics Fell 14.5% in November?

Is This Why Sarepta Therapeutics Fell 14.5% in November?

What happened? Shares of Sarepta Therapeutics (NASDAQ:SRPT), a commercial-stage biotech focused on rare diseases, fell 14% in November, according to S&P Global Market Intelligence. That move stands in sharp contrast to the gains showed by the biotech sector in general, as measured by the First Trust NYSE Arca Biotech ETF (NYSEMKT:FBT). So what? It was → Read More

3 Top Dividend Aristocrats to Buy in December

3 Top Dividend Aristocrats to Buy in December

Income investors know how important consistent growth in payouts can be, and the dividend stocks that you’ll find among the dividend aristocrats are among the best in the business at providing dividend growth. With requirements of at least a quarter-century of annual payout increases, dividend aristocrats prove their success through good times and bad. Let’s → Read More

Can Twilio Stock Bounce Back From Last Week's 13% Drop?

Can Twilio Stock Bounce Back From Last Week's 13% Drop?

One of this year’s most volatile IPOs keeps the stock gyrations coming. Shares of Twilio (NYSE:TWLO) declined 13.4% last week. There wasn’t any company-specific news triggering the sharp drop, but a weak quarterly report out of a fellow cloud-based applications provider didn’t help. Twilio’s stock was already trending lower before shares of Workday (NYSE:WDAY) took a → Read More

Here's Why ACADIA Pharmaceuticals Jumped 17.7% in November

Here's Why ACADIA Pharmaceuticals Jumped 17.7% in November

What happened Shares of Acadia Pharmaceuticals(NASDAQ:ACAD), a commercial-stage biopharma focused on diseases of the central nervous system, rose by more than 17% in November, according to data from S&P Global Market Intelligence. That was a large enough gain to outperform the red-hot biotech sector in general, as measured by the SPDR S&P Biotech ETF (NYSEMKT:XBI) So what → Read More

4 Ways You Can Have a Low Credit Score Despite Paying Your Bills on Time

4 Ways You Can Have a Low Credit Score Despite Paying Your Bills on Time

Whether you realize it or not, your credit score can have a major impact on more than just your finances. We often think of our credit score as influencing our ability to get a mortgage, take out a loan, or open a new credit account. But your credit score (also known as FICO score), which → Read More

1 Quote Reveals Why Gilead Sciences Hasn't Bought Anybody Yet

1 Quote Reveals Why Gilead Sciences Hasn't Bought Anybody Yet

Gilead Sciences (NASDAQ:GILD) needs to buy somebody.  The Hepatitis C / HIV behemoth has seen its price tank in 2016 as investor fears about growth slowing — and even reversing — have come true. Slashing prices to maintain its Hepatitis C market share has dramatically impacted Gilead’s top line, with overall revenue falling 9.6% year → Read More

Here's Why Amyris Stock Dropped 16.8% in November

Here's Why Amyris Stock Dropped 16.8% in November

What happened After a meteoric 220% rise from August to mid-October, shares of Amyris (NASDAQ:AMRS) fell 16.8% in November. A flurry of announced deals and partnership agreements weren’t enough to overcome the reality of the company’s financial performance. So what The company reported third-quarter 2016 earnings on Nov. 2. At first glance, there was plenty → Read More

Why Smith & Wesson and Sturm, Ruger Stocks Sank in November

Why Smith & Wesson and Sturm, Ruger Stocks Sank in November

What happened November was a strange month for gun stocks. Over the course of last month, shares of two of the biggest names in guns — Smith & Wesson (NASDAQ:SWHC) and Sturm, Ruger (NYSE:RGR) — both declined sharply. According to data from S&P Global Market Intelligence, Smith & Wesson stock dropped 10.5% in November, while → Read More

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.